Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDEAYA Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PHASE 2/3 TRIAL OF THE DAROVASERTIB AND CRIZOTINIB COMBINATION IN 1L HLA-A2-NEGATIVE METASTATIC UVEAL MELANOMA (MUM) ON TRACK TO REPORT MEDIAN PFS DATA BY YEAR-END 2025; POTENTIAL TO ENABLE A U.S. ACCELERATED APPROVAL FILING FIRST-REPORTED MEDIAN OVERALL SURVIVAL DATA IN OVER 40 1L MUM PATIENTS FROM SINGLE-ARM PHASE 2 TRIAL OF THE DAROVASERTIB AND CRIZOTINIB COMBINATION TO BE PROVIDED AT A MEDICAL CONFERENCE IN 4Q 2025 PHASE 2 DATAFROM OVER 90 PLAQUE BRACHYTHERAPY AND ENUCLEATION PRIMARY UVEAL MELANOMA (UM) PATIENTS TREATED WITH DAROVASERTIB IN THE NEOADJUVANT SETTING WILL BE SHARED AS A PROFFERED PAPER ORAL PRESENTATION AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) IN 4Q 2025 FIRST-IN-HUMAN PHASE 1 CLINICAL EFFICACY AND SAFETY DATA FROM OVER 70 SCLC PATIENTS TREATED WITH IDE849 (DLL3 TOP1I ADC) WILL BE PROVIDED AS AN ORAL PRESENTATION AT THE IASLC 2025 WORLD CONFERENCE ON LUNG CANCER ON SEPTEMBER 7 TH, 2025 IDEAYA 10-YEAR ANNIVERSARY R&D DAY WILL FEATURE MULTIPLE CLINICAL DATA UPDATES, INCLUDING FROM OVER 20 PLAQUE BRACHYTHERAPY PATIENTS IN THE PHASE 2 TRIAL OF DAROVASERTIB AS NEOADJUVANT THERAPY FOR PRIMARY UM AND FROM TWO EXPANSION COHORTS IN THE PHASE 1 COMBINATION TRIAL OF IDE397 ANDTRODELVY (SACITUZUMAB GOVITECAN-HZIY) IN MTAP-DELETION UROTHELIAL CANCER THREE IND SUBMISSIONS ARE ON TRACK BY YEAR-END 2025, INCLUDING IDE892 (PRMT5), IDE034 (B7H3/PTK7 BISPECIFIC TOP1I ADC) AND IDE574 (KAT6/7) ~$992 MILLION OF CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF JUNE 30, 2025; ANTICIPATED TO FUND OPERATIONS INTO 2029 SOUTH SAN FRANCISCO, CALIF. , AUG. 5, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), AN ONCOLOGY COMPANY COMMITTED TO ADVANCING THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TRANSFORMATIVE PRECISION MEDICINES TO ADDRESS UNMET MEDICAL NEEDS IN CANCER, PROVIDED A BUSINESS UPDATE AND ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDEDJUNE 30, 2025.

IDEAYA BIOSCIENCES, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SOUTH SAN FRANCISCO, CALIF. , AUG. 1, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A PRECISION MEDICINE ONCOLOGY COMPANY COMMITTED TO THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPEUTICS, TODAY ANNOUNCED THAT, ON JULY 31, 2025, THE COMPENSATION COMMITTEE OF IDEAYA'S BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 31,400 SHARES OF THE COMPANY'S COMMON STOCK TO A NEWLY HIRED EMPLOYEE.

IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

THE PRESENTATION WILL INCLUDE DATA FROM OVER 90 PATIENTS IN BOTH THE PLAQUE BRACHYTHERAPY AND ENUCLEATION-ELIGIBLE COHORTS DAROVASERTIB HAS RECEIVED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR USE IN NEOADJUVANT UVEAL MELANOMA FOR SUBJECTS REQUIRING ENUCLEATION INITIATED A MULTI-SITE, GLOBAL RANDOMIZED PHASE 3 NEOADJUVANT REGISTRATIONAL TRIAL IN PRIMARY UVEAL MELANOMA (OPTIMUM-10) IN Q3 2025 SOUTH SAN FRANCISCO, CALIF. , JULY 24, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A LEADING PRECISION MEDICINE ONCOLOGY COMPANY, TODAY ANNOUNCED THAT RESULTS FROM A MULTI-SITE GLOBAL PHASE 2 STUDY OF NEOADJUVANT DAROVASERTIB IN PRIMARY UVEAL MELANOMA WAS ACCEPTED FOR A PROFFERED PAPER ORAL PRESENTATION AT THE 2025 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) MEETING, TAKING PLACE ON OCTOBER 17-21 IN BERLIN, GERMANY.

IDEAYA BIOSCIENCES ANNOUNCES PROFFERED PAPER ORAL PRESENTATION AT ESMO 2025 FOR PHASE 2 CLINICAL TRIAL OF NEOADJUVANT DAROVASERTIB IN PRIMARY UVEAL MELANOMA

SOUTH SAN FRANCISCO, CALIF. , JULY 23, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A PRECISION MEDICINE ONCOLOGY COMPANY COMMITTED TO THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPEUTICS, ANNOUNCED IT WILL HOST AN IN-PERSON AND VIRTUAL R&D DAY ON SEPTEMBER 8, 2025 FROM 8:00AM TO 10:00AM ET IN NEW YORK CITY TO PRESENT MULTIPLE CLINICAL DATA UPDATES ACROSS THE PIPELINE AND HIGHLIGHT THE NEXT KEY DRIVERS OF GROWTH AND UPCOMING MILESTONES.

IDEAYA BIOSCIENCES ANNOUNCES 10-YEAR ANNIVERSARY R&D DAY ON SEPTEMBER 8, 2025 TO PRESENT MULTIPLE CLINICAL DATA UPDATES AND OUTLINE FUTURE GROWTH STRATEGY

CLINICAL EFFICACY AND SAFETY DATA WILL BE PRESENTED FROM OVER 70 SMALL-CELL LUNG CANCER (SCLC) PATIENTS IN HENGRUI'S ONGOING, MULTI-SITE, OPEN LABEL PHASE 1 TRIAL DATA WILL INCLUDE PATIENTS FROM THE DOSE ESCALATION AND AT MULTIPLE EXPANSION DOSES U.S. PHASE 1 TRIAL OF IDE849 IN SCLC PATIENTS INITIATED IN 3Q 2025 JIANGSU, CHINA AND SOUTH SAN FRANCISCO, CALIF. , JULY 22, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A LEADING PRECISION MEDICINE ONCOLOGY COMPANY, AND JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

IDEAYA BIOSCIENCES AND HENGRUI PHARMACEUTICALS ANNOUNCE ORAL PRESENTATION AT IASLC 2025 WORLD CONFERENCE ON LUNG CANCER FOR IDE849 (SHR-4849), A POTENTIAL FIRST-IN-CLASS DLL3-TOP1 ADC

SOUTH SAN FRANCISCO, CALIF. , JULY 21, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A PRECISION MEDICINE ONCOLOGY COMPANY COMMITTED TO THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPEUTICS, ANNOUNCED ITS PARTICIPATION IN THE UPCOMING INVESTOR RELATIONS EVENT.

IDEAYA BIOSCIENCES TO PARTICIPATE IN UPCOMING JULY 2025 INVESTOR RELATIONS EVENT

SOUTH SAN FRANCISCO, CALIF. , JUNE 27, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A PRECISION MEDICINE ONCOLOGY COMPANY COMMITTED TO THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPEUTICS, TODAY ANNOUNCED THAT, ON JUNE 26, 2025, THE COMPENSATION COMMITTEE OF IDEAYA'S BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 95,600 SHARES OF THE COMPANY'S COMMON STOCK TO A NEWLY HIRED EMPLOYEE.

SOUTH SAN FRANCISCO, CALIF. , JUNE 2, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A PRECISION MEDICINE ONCOLOGY COMPANY COMMITTED TO THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPEUTICS, ANNOUNCED ITS PARTICIPATION IN THE UPCOMING INVESTOR RELATIONS EVENTS.

IDEAYA BIOSCIENCES TO PARTICIPATE IN UPCOMING JUNE 2025 INVESTOR RELATIONS EVENTS

SOUTH SAN FRANCISCO, CALIF. , MAY 30, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A PRECISION MEDICINE ONCOLOGY COMPANY COMMITTED TO THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPEUTICS, TODAY ANNOUNCED THAT, ON MAY 29, 2025, THE COMPENSATION COMMITTEE OF IDEAYA'S BOARD OF DIRECTORS GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 664,600 SHARES OF THE COMPANY'S COMMON STOCK TO NINE NEWLY HIRED EMPLOYEES.

~$1.05 BILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2025, AND AN UPDATED CASH RUNWAY GUIDANCE INTO 2029; COMMERCIAL READINESS ACTIVITIES ONGOING OVER 300 PATIENTS ENROLLED IN DAROVASERTIB AND CRIZOTINIB REGISTRATIONAL 1L HLA-A2-NEGATIVE MUM TRIAL; TARGETING MEDIAN PFS RESULTS BY YE 2025 TO ENABLE POTENTIAL ACCELERATED APPROVAL FILING SUCCESSFUL FDA TYPE D MEETING COMPLETED TO FINALIZE DAROVASERTIB PH3 REGISTRATIONAL TRIAL DESIGN AND RECEIVED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION IN NEOADJUVANT UM TARGETING THREE DAROVASERTIB PROGRAM CLINICAL DATA UPDATES AT MEDICAL CONFERENCES IN 2025, INCLUDING 1L MUM MOS RESULTS IN >40 PATIENTS AND NEOADJUVANT UM DATA IN >90 PATIENTS IDE849 (DLL3 TOP1 ADC) PHASE 1 INITIATED IN U.S., AND PARTNER HENGRUI TARGETING CLINICAL DATA UPDATE IN OVER 40 SCLC PATIENTS AT A MEDICAL CONFERENCE IN Q3 2025 ORAL PRESENTATION OF POTENTIAL BEST-IN-CLASS PHASE 1 WRN INHIBITOR IDE275 AT AACR 2025 THREE ADDITIONAL IND-FILINGS TARGETED IN 2025: PRMT5, B7H3/PTK7 ADC, AND KAT6/7 SOUTH SAN FRANCISCO, CALIF. , MAY 6, 2025 /PRNEWSWIRE/ -- IDEAYA BIOSCIENCES, INC. (NASDAQ: IDYA), A PRECISION MEDICINE ONCOLOGY COMPANY COMMITTED TO THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPEUTICS, PROVIDED A BUSINESS UPDATE AND ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER THAT ENDEDMARCH 31, 2025.

IDEAYA Biosciences, Inc.

IDYA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IDEAYA Biosciences, Inc.

IDYA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IDYA